Market Overview

Acer Therapeutics Shares Plunge On FDA Complete Response Letter

Acer Therapeutics Shares Plunge On FDA Complete Response Letter

Acer Therapeutics Inc (NASDAQ: ACER) shares were trading down more than 75% Tuesday after it received a letter from the Food and Drug Administration regarding its drug application for Edsivo in the treatment of vascular Ehlers-Danlos syndrome.

The FDA said it is necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS.

The rare disorder is caused by a gene mutation affecting a major protein, which causes weakness in vessel walls and hollow organs.

Acer Therapeutics plans to request a meeting to discuss the FDA’s response.

“We remain committed to working closely with the FDA to fully understand its response,” CEO Chris Schelling said in a statement. “We expect to respond to the FDA in the third quarter of this year." 

Acer Therapeutics shares were down 77.36% at $4.36 at the time of publication. 

Related Links:

Genfit Partners With Terns Pharma To Develop, Commercialize Elafibranor In China

7 Stocks To Watch For June 25, 2019

Posted-In: Biotech News FDA Movers Trading Ideas General Best of Benzinga


Related Articles (ACER)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Canopy Growth CEO Looks To The 'Pharmaceutical World' After String Of M&A Deals

Fintech Focus Rewind: This CEO Wants To Make Business Expenses Easier